|I. General information|
|Background:||The I 2.1 cell line is a FADD mutant of the wild-type Jurkat cell line A3 (see ATCC -CRL-2570). Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. Ref
ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks. Ref Two of these ICR-191 treated clones have been deposited at the ATCC . They are I 9.2 (ATCC CRL-2571), a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2.1 (ATCC CRL-2572), a clone with a mutation in the adaptor FADD.
|Species:||Homo sapiens, human|
|Disease:||acute T cell leukemia|
|DNA Profile:||Amelogenin: X,Y
Cobioer’s Cell Line Authentication Service
We strongly suggest to purchase the complete medium from Cobioer.
|Comments:||Unlike the parental line A3 that does express FADD, the I 2.1 cell line does not express FADD protein by immunoblot analysis and is completely resistant to Fas-induced death. Complementation of the I 2.1 cell lines with wild-type FADD restores Fas-mediated apoptosis. Fas activation of caspase-2, caspase-3, caspase-7, and caspase-8 is completely defective in the FADD mutant cell line I 2.1. Ref
This cell line can be used to study the role of FADD in apoptotic signaling pathways in the absence of overxpression.
For more information, please contact Cobioer (4008-750-250).